An Extension Study of CORLUX in the Treatment of Endogenous Cushing's Syndrome
Status:
Completed
Trial end date:
2012-09-01
Target enrollment:
Participant gender:
Summary
Participants in study C-1073-400 (NCT00569582) will be invited to participate in this
extension study to examine the long term safety of mifepristone in the treatment of the signs
and symptoms of endogenous Cushing's syndrome. Total treatment duration may be up to 12
months or longer at the discretion of the Investigator.